Drug policy experts accuse industry and patient groups of ‘fearmongering’ with concerns about new drug-pricing rules
OTTAWA — Industry groups and patient advocates are raising concerns about the federal government’s new drug-pricing rules, claiming they will limit access to much-needed drugs and discourage drug companies from investing in Canada.
But drug policy experts say the changes, which the government estimates will yield savings of $13.2 billion over the next decade, are long overdue, and argue that pharmaceutical companies are simply fearmongering to protect their bottom line.
But Marc-André Gagnon, an associate professor of health policy at Carleton University, said pharmaceutical companies are simply “fearmongering” in anticipation of reduced profits from patented drug sales. He said the regulatory changes are overdue, and pointed to the value-for-money consideration as a step in the right direction. “We need to stop paying for everything at any price,” he said.